Alcan Investor Workshop

Made public by

sourced by PitchSend

22 of 31

Creator

Alcantara logo
Alcantara

Category

Healthcare

Published

2006

Slides

Transcriptions

#1#2#3#4#5#6Business Environment & Competitive Position Evolution of Raw Material Prices We have experienced a dramatic rise in our raw material prices since 2004. The trend has been flatter in 2006 for resins, though not for aluminum. Raw material purchases Paper 4% Aluminum 21% Other 12% Chemical products 14% 2006 ALCAN INC. Film 27% Resins 22% Index (1980=100) 250 200 150 100 50 0 1980 1982 1984 LDPE Resin Aluminum 1986 1988 1990 1992 1994 1996 Chart based on nominal prices 1998 ALCAN 2000 LDPE resin price increased by 70% since 2002 2002 2004 2006 Slide 6#7Business Environment & Competitive Position Effect of Cost Pressures since 2002 Unprecedented rise in raw material prices significantly squeezed industry margins NA Flexibles Industry - 2001-2005 Global Packaging Companies - 2001-2005 Source: Harris Nesbitt, May 2006 Bemis, Sealed Air, Winpak, Huhtamaki, Amcor, Alcan Packaging LLDPE Europe/NA Index 2001-100 Gross Margin % Average TTM Gross Margin vs. Resin Pricing Flexible Packaging Companies 26% 25% 24% 23% 22% 21% 20% 2001 3Q01 2Q02 3Q02 2003 ITTM Gross Margin 3Q03 2004 3Q04 200 por acos aco 3Q05 LLDPELPDE $1.00 $0.90 $0.80 $0.70 $0.60 $0.50 $0.40 $0.30 Resin Price ($ per lb) EBITDA Margin % EBITDA % Sales 18% 16% 14% 12% 10% 8% 6% 4% 2% 0% + Hr 2001 . 2002 ALCAN + 2003 2004 2005 ▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬ 180 160 140 120 100 80 60 40 20 0 ➤ Average EBITDA margin decline of 3.7% from the peak of 2002, and 2.2% from the more average years of 2001 & 2003 LLDPE Price Index (2001=100) Weakening economic conditions, especially in Europe, have also been a significant factor contributing to declining margins over the period 2002-2005 ©2006 ALCAN INC. Slide 7#8#9Strategic Progress III Our margins have been relatively more resistant to cost pressures, due to significant progress in strategy implementation. Setting Operating Excellence as a foundation of our success ■ Rationalization of our portfolio ALCAN ■ Focus on growing and attractive market segments 2006 ALCAN INC. Slide 9#10#11#12#13#14#15#16#17#18#19#20#21#22#23#24#25#26#27#28#29

Download to PowerPoint

Download presentation as an editable powerpoint.

Related

Fiscal 3Q Investor Presentation image

Fiscal 3Q Investor Presentation

Healthcare

FY23 Full-Year Results Presentation image

FY23 Full-Year Results Presentation

Healthcare

Healthcare Network P&L Statement and Expansion Projects image

Healthcare Network P&L Statement and Expansion Projects

Healthcare

Accreditation and Quality Assurance Overview image

Accreditation and Quality Assurance Overview

Healthcare

Investment Highlights image

Investment Highlights

Healthcare

Investor Presentation image

Investor Presentation

Healthcare

IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update image

IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update

Healthcare

BioAtla Investor Presentation Deck image

BioAtla Investor Presentation Deck

Healthcare